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Histone deacetylaseIncreasing hepatic stellate cell (HSC) death is a very attractive approach for limiting liver ﬁbrosis. Tyrosine kinase
inhibitors havebeen shown to have anti-ﬁbrotic properties, but themechanisms are poorly understood. Here,we
identiﬁed the mechanism of action of the second-generation tyrosine kinase inhibitor nilotinib in inducing HSC
death. Human HSC line (LX-2) and rat HSCs were treated with nilotinib and its predecessor, imatinib, in the ab-
sence or presence of various blockers, known to interfere with death signaling pathways. Nilotinib, but not
imatinib, induced progressive cell death of activated, but not quiescent, HSCs in a dose-dependent manner. Ac-
tivated HSCs died through apoptosis, as denoted by increased DNA fragmentation and caspase activation, and
through autophagy, as indicated by the accumulation of autophagic markers, light chain (LC)3A-II and LC3B-II.
Although inhibition of caspaseswith Z-VAD-FMK suppressed nilotinib-induced HSCs' apoptosis, therewas no in-
crease inHSCs' survival, because autophagywas exacerbated. However, blocking themitochondrial permeability
transition pore (mPTP) opening with cyclosporin A completely abolished both apoptosis and autophagy due to
nilotinib. Moreover, nilotinib treatment decreased the protein expression of histone deacetylases 1, 2 and 4. In-
terestingly, pretreament with C646, a selective p300/CBP histone acetyl transferase inhibitor, resulted in divert-
ing nilotinib-induced apoptosis and autophagy towards necrosis. In conclusion, the identiﬁcation of mPTP as a
target of nilotinib in activated HSCs suggests coordinationwith histone deacetylases inhibition to induce apopto-
sis and autophagy. Thus, our study provides novel insights into the anti-ﬁbrotic effects of nilotinib.
© 2013 Published by Elsevier B.V.1. Introduction
Hepatic ﬁbrosis is a wound-healing response characterized by
the accumulation of extracellular matrix (ECM) proteins as a result
of chronic liver injury. Activation of hepatic stellate cells (HSCs), the
main source of ECM proteins, represents a crucial event in the patho-
genic sequence of ﬁbrosis and thus, provides an important framework
to deﬁne potential strategies for anti-ﬁbrotic therapy [1]. Beside the
inhibition of ﬁbrogenic cytokines, the induction of HSC death is now
considered an effective strategy for the resolution of hepatic ﬁbrosis
[2,3]. The ideal cell death strategy should not alert the hepatic inﬂam-
matory response and should selectively target activated HSCs while
maintaining quiescent HSCs. In contrast to the unorganized way of
death “necrosis” that triggers the inﬂammatory response, apoptosis
and autophagy proceed with the participation of organized and con-
trolled cellular processes, which achieve a cleaner cellular execution [4].epartment of InternalMedicine,
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al).
sevier B.V.Death by apoptosis commonly signals through the activation of
initiator and executioner caspases, resulting in the formation of apo-
ptotic bodies that are removed by phagocytes [5]. The autophagic
pathway involves the formation of a membrane around a targeted re-
gion of the cell, resulting in the autophagosome formation, which
fuses with a lysosome to form an autophagolysosome where the con-
tents are degraded via acidic lysosomal hydrolases [6,7]. Autophagy
has been reported to be involved in the degradation of long-lived pro-
teins and organelles in order to promote survival and activation of
HSCs [8]. Most recently, autophagy has been implicated in the release
of lipid droplets from HSCs that further promoted ﬁbrogenesis of ac-
tivated HSCs [9]. Paradoxically, Rickmann et al. have reported that
tocotrienols counteracted pancreatic ﬁbrogenesis through the induc-
tion of apoptosis and autophagy in activated pancreatic stellate cells
[10]. Thus, the contribution of autophagy to cell survival or death de-
pends on the type of stimulus and the cell context.
Nilotinib is a second-generation tyrosine kinase inhibitor that was
originally developed for treatment of chronic myeloid leukemia resis-
tant to treatment with its predecessor, imatinib [11]. There has been a
recent interest regarding the potential efﬁcacy of nilotinib in the
treatment of the most common and progressive forms of ﬁbrosis.
These include treatment of pulmonary ﬁbrosis [12], renal ﬁbrosis
1993M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–2003[13], dermal ﬁbrosis [14] and hepatic ﬁbrosis [15–17]. However, the
molecular mechanisms involved in nilotinib anti-ﬁbrotic effects
have not been completely characterized.
In the present study, we provide novel insights into the anti-ﬁbrotic
effects of nilotinib in vitro using human HSC line (LX-2) and rat HSCs.
Herein, we report that nilotinib, but not imatinib, induces apoptosis and
autophagic cell death of activated HSCs through the intrinsic mitochon-
drial pathway. Notably, when nilotinib-induced apoptosis was blocked
by caspase inhibition, cells failed to survive not due to a switch towards
necrosis, but because autophagy was exacerbated. Thus, it is presumable
that nilotinib is triggering autophagy as an alternative process of cell
death rather than a survival mechanism. Besides, we reveal novel targets
for nilotinib, including histone deacetylases (HDACs) 1, 2 and 4 that we
believe to be involved in nilotinib-induced cytotoxicity of HSCs.
2. Materials and methods
2.1. Cell culture and treatments
LX-2 cells, immortalized human HSCs, were obtained from Dr.
Scott Friedman (Mount Sinai School of Medicine) and were culturedFig. 1. Nilotinib inhibits chemotaxis, upregulation of COL1A1 and TGF-β1 mRNA, and activati
nilotinib treatments for 24 h on chemotaxis (A), upregulation of COL1A1(B–C) and TGF-β1
independent experiments. Statistically signiﬁcant differences are indicated as: *P b 0.05, **P
PDGF (10 ng/ml) or TGF-β1 (2.5 ng/ml); +P b 0.05, ++P b 0.01 and +++P b 0.001 versin Dulbecco's modiﬁed eagle medium (DMEM, high glucose) plus 5%
(v/v) FBS and 1% (v/v) penicillin–streptomycin [18]. Primary rat HSCs
were routinely prepared by collagenase/pronase digestion of liver
using a perfusion system andwere isolated using the Optiprep gradient
as previously described [19,20]. Primary rat HSCswere cultured inM-199
medium [10% v/v FBS + 1% v/v penicillin–streptomycin + 2 mM
L-glutamine + amphotericin B (2.5 μg/ml) + gentamicin (20 μg/ml)].
Our studies were conducted according to the institutional ethical guide-
lines of Yale University. Imatinib and nilotinib were freshly prepared as
20 mM stock solution in DMSO and ﬁlter sterilized using a syringe ﬁlter
(0.2 μm). After 24 h of fasting at 0.2% (v/v) FBS, LX-2 cells were treated
with imatinib or nilotinib (10 and 20 μM) with 0.2% (v/v) FBS for 24 h,
in the absence or presence of various agents dissolved in DMSO and
applied 1 h before, such as Z-VAD-FMK (50 μM), cyclosporin A (20 μM),
3-methyladenine (10 mM), AEBSF (100 μM), UCF-101 (2 μM) and
C646 (1 μM). In clinical practice, the steady-state peak plasma concen-
tration of nilotinibwas shown to be 4.27 μMafter oral administration of
400 mg nilotinib twice daily [21]. We observed that 5 μM of nilotinib
produced the same effects as 20 μM after longer time (48 h rather
than 24 h). Thus, the used concentrations of nilotinib are in the same
in vivo range.on of HSCs, and induces progressive cell death of activated HSCs. Effects of imatinib and
(D) mRNA, activation (E–F) and viability (G) of HSCs. Data are means ± SE of at least 4
b 0.01 and ***P b 0.001 versus CTRL; #P b 0.05, ##P b 0.01 and ###P b 0.001 versus
us imatinib (10 μM); ΔΔΔP b 0.001 versus imatinib (20 μM).
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The migration of LX-2 cells was studied using a 24-well plate
equipped with transwell inserts (8-μm-pore polycarbonate-free ﬁlters,
purchased fromCostar®, Corning, NY, USA) as previously described [22]
with a slight modiﬁcation. Brieﬂy, 250 μl of the cell suspension was
added to the upper chamber of the transwell (2 × 104 cells/well). To
the lower chamber, 500 μl of DMEM (containing 0% v/v FBS) was
added per well. After 2 h, LX-2 cells were pretreated with imatinib or
nilotinib (10 and 20 μM) 1 h before the addition of PDGF (10 ng/ml).
After 24 h, the cells were ﬁxed and the lower surface of the membrane
was stained using hematoxylin–eosin, and the upper surface of
the membrane was gently scraped. Thereafter, 6 random ﬁelds per
transwell were photographed using the high-power ﬁeld (200×), and
counted for the migrated cells.
2.3. Reverse transcriptase-polymerase chain reaction (RT-PCR)
Total RNA was extracted using TRIzol reagent (Invitrogen, Carlsbad,
California, USA) according to the manufacturer's instructions. Brieﬂy,Fig. 2. Nilotinib, but not imatinib, induces apoptosis and DNA damage of activated HSCs in a
and late (lower and upper right quadrant, respectively) apoptosis percentage (A–B) as asses
protein expression of PARP/cleaved PARP (C–D), Rb, p53 and their fold changes (E–J) in HSC
independent experiments. Statistically signiﬁcant differences are indicated as: *P b 0.05, **P
and +++P b 0.001 versus the corresponding imatinib (10 μM) group; ΔP b 0.05, ΔΔP b 0LX-2 cells were lysed with the reagent, chloroform was added, and
the cellular RNA was precipitated by isopropyl alcohol. After washing
with 75% ethanol, the RNA pellet was dissolved in RNAse free water.
Total RNA was reverse transcribed to cDNA using the transcriptor ﬁrst
strand cDNA (Roche Applied Science, Mannheim, Germany). RNA
(1 μg) in 13 μl of RNAse free water was added to 1 μl of oligo(dT)18
primer. After incubating at 65 °C for 10 min in the thermal cycler, 4 μl
of 5× reverse transcriptase buffer, 1 μl of deoxynucleotide mix, 0.5 μl
of protector RNAse inhibitor and 0.5 μl of transcriptor reverse transcrip-
tasewere added (total volume of 20 μl). The reactionwas performed for
60 min at 50 °C (cDNA synthesis) and 5 min at 85 °C (enzymedenatur-
ation). The previously prepared cDNA samples were prediluted ﬁrst
1:10 by PCR-grade water. For every cDNA ampliﬁcation, 4.9 μl of the di-
luted sample was loaded as duplicate in the 384-multiwell plate, and
5 μl of LightCycler® 480 probes master 2× (Roche Applied Science,
Mannheim, Germany) in addition to 0.1 μl of human TGF-β1 or
COL1A1 TaqMan primer-probe mixture (Applied Biosystems, Foster
City, California, USA). The housekeeping gene GAPDHwas used as a ref-
erence gene for normalization and PCR-grade water was used as a neg-
ative control. Comparative quantitative real time PCR was performeddose-dependent manner. Effects of imatinib and nilotinib treatments for 24 h on early
sed by ﬂow cytometric analysis using AV-FITC (FL1-H) and PI (FL2-H) stainings, and the
s as assessed by the Western blot for the total lysates. Data are means ± SE of at least 4
b 0.01 and ***P b 0.001 versus the corresponding CTRL group; +P b 0.05, ++P b 0.01
.01 and ΔΔΔP b 0.001 versus the corresponding imatinib (20 μM) group.
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Mannheim, Germany) using the “Mono Color Hydrolysis Probe” format,
and the ΔΔCt method was used to determine the relative expression.
2.4. Western blotting
At the end, the cells werewashed twicewith ice-cold PBS and lysed in
100 μl of 1× RIPA buffer (Cell Signaling, Danvers, MA, USA) containing
MiniEDTA Protease inhibitor (Roche Applied Science Mannheim,
Germany) for 20 min on ice. The cell lysates were centrifuged at
12,000 g for 10 min at 4 °C. Protein concentrations were measured with
the Bradford assay. After denaturation, equal amounts of protein
(20 μg) were subjected to gel electrophoresis (150 V, 400 mA) using
NuPAGE® 4%–12% Bis–Tris mini gel (Invitrogen, Grand Island, NY, USA)
and transferred to PVDF membranes (Millipore, MA, USA) at 4 °C during
applying a transfer voltage of (120 V, 400 mA) for 90 min. After transfer,
the PVDFmembraneswere blockedwith TBST buffer containing 5% (w/v)
BSA at room temperature for 1 h. Without washing, one of the primary
antibodies (speciﬁed in the Supplementary Table 1) was added in the
TBST buffer containing 5% (w/v) BSA overnight (16 h) at 4 °C. Thereafter,
the blot waswashed 3 times in TBST buffer to get rid of the extra primary
antibody and was incubated with secondary antibody (HRP-conjugated)
diluted with TBST buffer containing 5% (w/v) BSA for 1 h. The blot was
washed 3 times in TBST buffer to get rid of the extra secondary antibody,
and an enhanced chemiluminescent kit substrate (Thermo Scientiﬁc,
Waltham, MA, USA) was added for developing. Then, the blot was devel-
oped against a sensitive ﬁlm in the dark room for certain time, and the
ﬁlm was visualized by Kodak Image Reader. Quantitation of proteinFig. 3.Nilotinib-induced apoptosis of HSCs is associatedwith activation of caspases. Effects of imatin
(A), cleaved caspase 9 (B), cleaved caspase 3 (C), pro-caspase 7/cleaved caspase 7 (D) and the fold
SE of at least 4 independent experiments. Statistically signiﬁcant differences are indicated as: *P b
ΔΔP b 0.01 versus imatinib (20 μM); ΔP b 0.05 and ΔΔP b 0.01 versus imatinib (20 μM).expression was determined by densitometry of digitalized images by
using TotalLab software v6 (Newcastle, Tyne, England).
2.5. Flow cytometric analysis of apoptosis
LX-2 cells were treated with imatinib or nilotinib (10 and 20 μM)
for 24 h, in the absence or presence of the previously mentioned
agents, but in the medium containing 1% rather than 0.2% (v/v) FBS.
HSCs were labeled with annexin V-ﬂuorescein isothiocyanate (AV-
FITC, BD Pharmingen, San Joes, CA) and propidium iodide (PI) (Sigma)
for ﬂow cytometric analysis (Becton Dickinson, USA) using Cell Quest
software as previously described [16].
2.6. Detection of autophagic vacuoles
After growing LX-2 cells to 70% conﬂuence on glass coverslips in 12
well-plates, the medium was changed from 5% DMEM to 1% DMEM.
After 24 h of fasting, LX-2 cells were treated with 20 μM imatinib or
nilotinib for further 24 h. Thereafter, LX-2 cells were incubated with
0.05 mM monodansyl cadaverine in PBS at 37 °C for 10 min. The cells
were next washed 4 times with PBS and observed under a ﬂuorescence
microscope at excitation wavelength of 380 nm and emission wave-
length of 525 nm as previously described [23].
2.7. Immunocytochemistry
LX-2 cells were cultured on glass coverslips in 24 well-plates and
grown to approximately 60% conﬂuence for three days to promote theib andnilotinib treatments for 24 hon the protein expression of pro-caspase 9/pro-caspase 3
changes of procaspases (E–G) as assessed for the total lysates of LX-2 cells. Data aremeans ±
0.05 and ***P b 0.001 versus CTRL;+P b 0.05 and+++P b 0.001 versus imatinib (10 μM);
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treatedwith imatinib or nilotinib (10 and 20 μM)with 0.2% (v/v) FBS for
3 h. Then, the cells were then washed twice with serum free media
(DMEM) and then ﬁxed in 4% paraformaldehyde in PBS for 30 min.
After ﬁxation, the cells were washed twice with PBS and then
permeabilised with PBS containing 0.1% (v/v) triton X-100 for 30 min.
They were next washed twice with PBS and incubated with blocking so-
lution (5% w/v BSA in PBS) for 1 h. Primary antibody (NF-κB, 1:200 in
blocking solution) was added to the cells and incubated at 4 °C over-
night. In the next day, the cells were washed three times with DPBST
and incubated with the secondary antibody (1:2000) at room tempera-
ture for 1 h. Then, the cells were washed three times with DPBST,
and DAB peroxidase substrate kit (Vector Laboratories, Burlingame
CA, USA) was then added for 5 min according the manufacturer's
instructions. Then, the slides were washed one time with water,
stained with hematoxylin and Permount® was used as the mounting
media. After 15 min, the edges were coated with nail polish to prevent
dryness of the mounting medium. Thereafter, 8 random ﬁelds per slide
were photographed (100×), and counted for the dark brown stained
nuclei.2.8. Statistical analysis
Datawere expressed asmean ± standard error (SE) ofmean. Statis-
tical evaluations of the results were carried out by means of one way
analysis of variance, followed by Tukey–Kramer multiple comparison
test. The level of signiﬁcance was set at P b 0.05. Statistical tests were
performed with GraphPad Instat V 3.05 (GraphPad Software Inc., San
Diego, CA, USA). Column bar graphs were performed with GraphPad
Prism V 5.00 (GraphPad Software Inc., San Diego, CA, USA).Fig. 4. Blockade of the mPTP opening, but not inhibition of caspases, prevents HSCs' de
(CSA,20 μM) on nilotinib (20 μM)-induced apoptosis as evaluated under the phase cont
(FL2-H) staining (B–C), and the protein expression of PARP/cleaved PARP (D–E) as assess
least 4 independent experiments. Statistically signiﬁcant differences are indicated as: *P b3. Results
3.1. Nilotinib inhibits chemotaxis, upregulation of COL1A1 and TGF-β1
mRNA, activation of HSCs and exhibits selective cytotoxicity towards
activated HSCs, but not quiescent cells
To examinewhether nilotinib and its predecessor, imatinib, could in-
hibit the chemotaxis of LX-2 cells, PDGF-BB-induced migration of LX-2
cells using the transwell inserts was studied. Nilotinib (20 μM) showed
the most prominent inhibitory effect against PDGF-BB-induced chemo-
taxis of LX-2 cells (Fig. 1A). We next investigated the effects of nilotinib
and imatinib on type I collagen synthesis in LX-2 cells in response to
PDGF-BB and TGF-β1 stimulations. Quantitative RT-PCR demonstrated
that both imatinib and nilotinib equally reduced PDGF-BB-induced
COL1A1 mRNA expression in a dose-dependent manner (Fig. 1B). On
the other hand, TGF-β1-induced elevation in COL1A1 mRNA expression
was signiﬁcantly reduced only by treatment with nilotinib (20 μM)
and nilotinib (10 μM) at P b 0.01 and P b 0.05, respectively, compared
with the TGF-β1-treated LX-2 cells (Fig. 1C). TGF-β1-induced elevation
in TGF-β1 mRNA expression was reduced signiﬁcantly (P b 0.001)
by nilotinib (10 and 20 μM), but not imatinib (10 and 20 μM), compared
with the TGF-β1-treated LX-2 cells (Fig. 1D). Nilotinib (20 μM), but
not imatinib, completely suppressed the protein expression of α-SMA,
a marker of HSC activation, due to spontaneous activation of rat HSCs
in culture media (day 11) (Fig. 1E and F). Besides, nilotinib, but
not imatinib, produced progressive cell death in LX-2 cells over a
period of 24 h in a dose-dependent fashion, as observed by
phase-contrast microscopy (Fig. 1G). To be considered a beneﬁcial
therapy for liver ﬁbrosis, nilotinib and, to a lesser extent, imatinib
demonstrated selective cytotoxicity toward transformed rat HSCs
(i.e. activation HSCs to MFBs) at various timing (day 5, 8 and 11ath induced by nilotinib. Effects of Z-VAD-FMK (Z-VAD, 50 μM) and cyclosporin A
rast microscope (A) and by ﬂow cytometric analysis using AV-FITC (FL1-H) and PI
ed by Western blotting for the total lysates of LX-2 cells. Data are means ± SE of at
0.05 and ***P b 0.001 versus CTRL; ∇∇∇P b 0.001 versus nilotinib (20 μM).
1997M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–2003after isolation, Supplementary Fig. 1), but failed to induce any apo-
ptosis for quiescent cells (day 1–3), which are not involved in
ﬁbrogenesis.
3.2. Nilotinib-induced cytotoxicity of HSCs is mainly apoptosis associated
with cleavage of caspases
Flow cytometric analysis using AV-FITC and PI stainings (Fig. 2A
and B) showed that nilotinib when used at 10 and 20 μM for 24 h
resulted in approximately 40% and 65% total apoptosis, respectively.
Besides, nilotinib induced cleavage of poly (ADP-ribose) polymerase
(PARP) in LX-2 cells in a dose dependent manner (Fig. 2C). Nilotinib
also increased the protein expression of p53 in both LX-2 andFig. 5. Nilotinib induced-cytotoxicity of HSCs involves autophagic cell death along with
cadaverine-labeled autophagolysosome vacuoles by ﬂuorescence microscopy (200×, A), a
and beclin-1 (I, K) as assessed by Western blotting for the total lysates of LX-2 cells. Data are
are indicated as: *P b 0.05, **P b 0.01 and ***P b 0.001 versus CTRL; +P b 0.05, ++P b 0
imatinib (20 μM).transformed rat HSCs (day 11), which correlated with the decreased
expression of the hypophosphorylated retinoblastoma (Rb) protein
(Fig. 2D–J). To examinewhether nilotinib-induced apoptosis was relat-
ed to caspases, we evaluated the effect of nilotinib on the expression of
pro-caspases in LX-2 cells. Compared with the control untreated and
imatinib treated cells, nilotinib (20 μM) treatment resulted in the
reduction of the expression of pro-caspase 9, pro-caspase 3 and
pro-caspase 7 in LX-2 cells, indicating a cleavage of these substrates
(Fig. 3). To conﬁrm that the apoptotic effects produced by nilotinib on
LX-2 cells were mediated by caspases cleavage, we veriﬁed that the
cleaved products of caspase 9, caspase 3 and caspase 7 were present
in the cells treated only with nilotinib (20 μM) and, to a lesser extent,
nilotinib (10 μM).apoptosis. Effects of imatinib and nilotinib treatments for 24 h on the monodansyl
nd the protein expression of LC3A-I/II and LC3B-I/II (B–D), Atgs 7, 3, 12 and 5 (E–J),
means ± SE of at least 4 independent experiments. Statistically signiﬁcant differences
.01 and +++P b 0.001 versus imatinib (10 μM); ΔP b 0.05 and ΔΔP b 0.01 versus
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pretreatment with cyclosporin A, but not Z-VAD-FMK
Next, we sought to investigatewhether the blockade of this apoptosis
with the pancaspase inhibitor Z-VAD-FMK (50 μM) would prevent
nilotinib-induced cytotoxicity. As assessed by ﬂow cytometric analysis,
Z-VAD-FMK seemed to prevent nilotinib-induced apoptosis. However,
by observing LX-2 Cells under the phase-contrast microscopy,
Z-VAD-FMK hardly hampered nilotinib-induced cytotoxicity of LX-2
(Fig. 4A, B and C), indicating that there are caspase independent path-
ways involved in nilotinib-induced cytotoxicity of LX-2. A key event of
the apoptotic cell death mediated by the intrinsic mitochondrial path-
way is the mitochondrial permeability transition pore (mPTP) opening.
To investigate whether the cytotoxic effect of nilotinib is mediated by
mPTP opening, we examined the effect of cyclosporin A, a mPTP blocker,
on nilotinib-induced cytotoxicity. Cyclosporin A completely hampered
nilotinib-induced cytotoxicity, as conﬁrmed by the ﬂow cytometric
analysis and the normal appearance of LX-2 cells.We also examined pre-
treatment with both Z-VAD-FMK and cyclosporin A on nilotinib-
induced, and we found that Z-VAD-FMK did not add any additive effect
to cyclosporin A. By Western blotting, we observed that nilotinib-
induced DNA damage, indicated by PARP cleavage, is signiﬁcantly
inhibited by Z-VAD-FMK, cyclosporin A and their combination (Fig. 4D
and E).
3.4. Nilotinib induced-cytotoxicity of HSCs involves autophagic cell death
in addition to apoptosis
Autophagy has also been implicated in a type of programmed cell
death type II called “autophagic cell death” that is different from apopto-
sis, which is a programmed cell death type I [24]. We next investigated
whether, beside apoptosis, nilotinib induced-cytotoxicity involves
autophagic cell death. By using the autoﬂuorescent monodansylFig. 6.Nilotinib-induced autophagy of HSCs is exacerbated by caspases inhibition, but inhibited
(CSA, 20 μM) on nilotinib (20 μM)-induced changes of the protein expression of LC3A-I/II and
LX-2 cells. Data are means ± SE of at least 4 independent experiments. Statistically signiﬁcant
and ∇∇P b 0.01 versus nilotinib (20 μM).cadaverine dye, we observed that nilotinib and to less extent imatinib in-
duced the formation of large autophagic vacuoles in LX-2 cells (Fig. 5A).
Moreover, nilotinib, and to a lesser extent, imatinib resulted in a pro-
nounced accumulation of autophagic markers, light chain 3 (LC3)A-II
and LC3B-II, as determined by Western blotting (Fig. 5B–D). To further
conﬁrm our ﬁndings, we analyzed the protein expression of Atg7,
which is involved in the conversion both LC3A-I and LC3B-I to LC3A-II
and LC3B-II, respectively. As determined by Western blotting, nilotinib
(10 and 20 μM) resulted in more than 2 fold increase in Atg7 (Fig. 5E
and F). The autophagic pathway is known to be initiated by an increase
in the protein expression of beclin-1 that is correlated with an increase
in the protein expression autophagy-related genes (Atgs) 3, 5 and 12,
resulting in conversion of LC3-I into LC3-II. Unexpectedly, nilotinib
(20 μM) resulted in almost 0.5 fold decrease, rather than increase, of
the protein expression of beclin-1, Atgs 3, 5 and 12 (Fig. 5E–K).3.5. Nilotinib-induced autophagy of HSCs is potentiated by Z-VAD-FMK,
but inhibited by cyclosporin A
We next hypothesized that the mPTP opening is the upstream
trigger of the autophagic cell death induced by nilotinib. To prove
this hypothesis, we tested again pretreatment with Z-VAD-FMK, cy-
closporin A and their combination on nilotinib-induced changes of
autophagic markers, LC3A-II/I and LC3B-II/I, as well as beclin-1. Inter-
estingly, we observed a severe increase in both LC3A-II/I and LC3B-II/I
protein expressions upon pretreatment with Z-VAD-FMK (Fig. 6A, B
and C), which correlated with an increase in beclin-1 protein expres-
sion. On the other hand, cyclosporin A clearly suppressed the increase
in both LC3A-II/I and LC3B-II/I protein expressions due to either
nilotinib or nilotinib + Z-VAD-FMK and restored the decrease in
beclin-1 protein expression, suggesting that the mPTP opening is in-
volved in nilotinib-induced autophagic cell death (Fig. 6D and E).by the mPTP opening blockade. Effects of Z-VAD-FMK (Z-VAD, 50 μM) and cyclosporin A
LC3B-I/II (A–C), and beclin-1 (D–E) as assessed byWestern blotting for the total lysates of
differences are indicated as: *P b 0.05, **P b 0.01 and ***P b 0.001 versus CTRL;∇P b 0.05
1999M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–20033.6. Nilotinib-induced cleavage of caspases is implicated in the cleavage
of beclin-1
Next, we hypothesized that nilotinib-induced cleavage of caspases
might be involved in the cleavage of beclin-1. To prove this hypothe-
sis, we tested again pretreatment with Z-VAD-FMK, the autophagy in-
hibitor 3-methyladenine and their combination on nilotinib-induced
changes of cleaved beclin-1. Interestingly, we observed a cleavage of
beclin-1 in LX-2 cells treated with nilotinib, which was inhibited
only by Z-VAD-FMK, indicating that beclin-1 is a substrate for cleaved
caspases induced by nilotinib (Fig. 7A and B). On the other hand,
3-methyladenine clearly suppressed the increase in both forms of
LC3-I and II, but did not affect cleaved beclin-1 and Parp, and did
not increase the viability (Fig. 7C, D, E and G). Notably, autophagic
ﬂux was increased by nilotinib, as indicated by the decreased protein
expression of p62 (Fig. 7D and F).3.7. Nilotinib decreases the protein expression of histone deacetylases
(HDACs) 1, 2 and 4 in HSCs
Inhibition of HDACs has been shown to mediate cell death via differ-
ent mechanisms, including apoptosis by the intrinsic and extrinsic path-
ways, and autophagic cell death, as well as other types of cell death. To
investigate whether nilotinib induced apoptosis might be related to the
inhibition of HDACs as the upstream signaling pathway, we examined
the effect of nilotinib on the protein expression of HDACs 1, 2 and 4 in
LX-2 cells. Interestingly, nilotinib treatment decreased the proteinFig. 7. Nilotinib-induced cleavage of caspases is implicated in the cleavage of beclin-1. Effe
(20 μM)-induced changes of the protein expression of cleaved beclin-1 (A–B), LC3A-I/II an
the total lysates of LX-2 cells, as well as the viability(G). Data are means ± SE of at le
**P b 0.01 and ***P b 0.001 versus CTRL; ∇P b 0.05, ∇∇P b 0.01 and ∇∇∇P b 0.001 versusexpression of HDAC1, HDAC2 and more pronouncedly HDAC4 in a dose
dependentmanner (Fig. 8A–D). Imatinib (20 μM)also resulted in a slight
decrease in HDACs 1, 2 and 4 protein expressions, when compared with
untreated control. We also investigated the protein expression of HDACs
3, 5 and 7 in LX-2 cell, but they could not be detected.
3.8. Nilotinib triggers NF-κB p65 nuclear translocation in HSCs
To examine whether nilotinib-induced apoptosis might be related
to the inhibition of the nuclear translocation of the anti-apoptotic
transcription factor nuclear factor-kappaB (NF-κB) p65, we evaluated
the expression of total, cytoplasmic and NF-κB p65 in LX-2 cells.
Nilotinib (10 and 20 μM) activated, rather than inhibited, NF-κB p65
nuclear translocation in LX-2 cells after 3 h, as observed by immuno-
cytochemistry (Fig. 9A and B) and Western blotting for different cell
fractions (Fig. 9C and D). By counting the dark brown stained nuclei
per ﬁeld (100×), nilotinib at 10 and 20 μM resulted in a 4 and 5.5
fold increase in NF-κB p65 nuclear translocation, respectively. Unlike
nilotinib, imatinib did not produce any signiﬁcant increase on the nucle-
ar translocation of NF-κB p65 in LX-2 cells with the same concentrations.
3.9. Nilotinib induced-cytotoxicity of HSCs does not involve serine proteases,
but histone acetylase transferases
In addition to caspase-dependent apoptosis and autophagic cell
death, we next hypothesized that serine proteases, including high tem-
perature requirementproteinA2 (HTRA2),might be involved in nilotinibcts of Z-VAD-FMK (Z-VAD, 50 μM) and 3-methyladenine (3-MA, 10 mM) on nilotinib
d LC3B-I/II (C), PARP/cleaved PARP and p62 (D–F) as assessed by Western blotting for
ast 4 independent experiments. Statistically signiﬁcant differences are indicated as:
nilotinib (20 μM).
Fig. 8. Nilotinib decreases the protein expression of HDACs 1, 2 and 4 in HSCs. Effects of imatinib and nilotinib treatments for 24 h on the protein expression of HDACs 1, 2 and 4 as
assessed by Western blotting for the total lysates of LX-2 cells. Data are means ± SE of at least 4 independent experiments. Statistically signiﬁcant differences are indicated as:
*P b 0.05 and ***P b 0.001 versus CTRL; +P b 0.05 and +++P b 0.001 versus imatinib (10 μM); ΔP b 0.05 and ΔΔP b 0.01 versus imatinib (20 μM).
2000 M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–2003cytotoxicity. To test this hypothesis, we tried the use of AEBSF (100 μM),
a broad spectrum serine protease inhibitor, and UCF-101 (2 μM), a selec-
tive HTRA2 inhibitor, on nilotinib-induced cell death. Pretreatment with
AEBSF failed to block nilotinib-induced cell death, but UCF-101 showed a
slight protection (Fig. 10A). To investigate whether the imbalance pro-
duced in histone acetylation due to nilotinib inhibition of HDACs might
be involved in cell death,we tested pretreatmentwith C646 (1 μM), a se-
lective p300/CBP histone acetyl transferase inhibitor. We observed that
C646 slightly inhibited nilotinib-induced cell death, but its use was asso-
ciatedwithmorphological changes in LX-2 cells (become rounded rather
star shaped). As assessed by ﬂow cytometric analysis (Fig. 10B and C), it
seemed that both UCF-101 and C646 signiﬁcantly resulted in reduction
of nilotinib-induced total apoptosis by approximately 41% and 55%,
respectively. However, these results should be cautiously interpreted,
because we observed that pretreatment with either UCF-101 or C646
resulted in 60% necrosis versus 30% necrosis for untreated and nilotinib
(20 μM) treated cell populations. Both AEBSF (100 μM) and C646
(1 μM), but not UCF-101 (2 μM), slightly decreased nilotinib-induced
PARP cleavage by 24% and 29%, respectively (Fig. 10D and F). We
observed that pretreatment with C646 produced a severe increase
in LC3A-II/I and LC3B-II/I ratios, which was signiﬁcant (P b 0.001)
not only from control, but also from nilotinib (20 μM)-treated cells
(Fig. 10E, G and H). Thus, the severe increase due to pretreatment
with C646 in LC3A-II/I and LC3B-II/I ratios is due to suppression of
LC3A-I and LC3B-I, respectively. These results suggest that the up-
stream signaling of LC3A-I and LC3B-I is not working, as conﬁrmed by de-
creased expression of beclin-1 (Fig. 10I). Pretreatment with AEBSF, but
not UCF-101, decreased the expression of both LC3A-I + LC3A-II and
LC3B-I + LC3B-II, but the ratios of both LC3A-II/LC3A-I and LC3B-II/
LC3B-I remained slightly higher than nilotinib (20 μM). Notably, we ob-
served that pretreatmentwith C646 repressed constitutive basal caspases
and there was no caspase cleavage, as denoted by pro-caspase 7 and
cleaved caspase 7, respectively.4. Discussion
A large amount of evidence supports the importance of HSCs
apoptosis during the regression of liver ﬁbrosis [25,26]. Thus, selec-
tive removal of activated HSCs through induction of programmed
death is a therapeutic strategy in hepatic ﬁbrosis. With respect to
the inhibitory effects of imatinib and nilotinib on chemotaxis, activa-
tion and collagen synthesis pathways in HSCs, we observed that the
application of nilotinib, but not imatinib, induces apoptosis of HSCs.
As an attempt to elucidate the molecular mechanism involved in
nilotinib-induced apoptosis, we observed that application of nilotinib
resulted in the cleavage of caspases and PARP, as well as extensive
DNA damage associated with elevation of p53 protein expression [27].
The decrease in Rb protein expression due to nilotinib suggests deregu-
lation of the cell cycle and subsequently, apoptosis of HSCs [28,29]. This
was further supported by the stimulation of NF-κBnuclear translocation
in LX-2 cells by nilotinib, because activation of the transcription factor
NF-κB results in up-regulation of not only anti-apoptotic genes, but
also pro-apoptotic genes [30,31].
Interestingly, pretreatment with cyclosporin A, but not Z-VAD-
FMK, blocked nilotinib-induced cytotoxicity. Most recently, Liu et al.
have shown that application of nilotinib with the same doses induced
upregulation of TRAIL receptors and ligands in HSCs as conﬁrmed by
ﬂow cytometric analysis and Western blot, respectively [32]. Howev-
er, there was no impressive difference in TRAIL ligand expression
levels between nilotinib (5, 10 and 20 μM) treated cells and the
untreated control by observing their data. According to our data, the
mPTP opening plays a crucial role in the cytotoxic effect of nilotinib
as conﬁrmed by the use of cyclosporin A, whereas the extrinsic path-
way mediated by the death ligand TRAIL has a minor role in this
apoptosis.
A novel aspect revealed by this study is that nilotinib triggers
HSCs' death not only by the classical apoptosis, but also through the
Fig. 9. Nilotinib, but not imatinib, triggers the nuclear translocation of NF-κB p65 in HSCs. Effects of imatinib and nilotinib treatments for 3 h on NF-κB p65 nuclear translocation in
LX-2 as evaluated by immunocytochemistry and counting the dark brown nuclei per ﬁeld (100×, A–B), and by Western blot for different cell fractions (C–D). Data are means ± SE
of at least 4 independent experiments. Statistically signiﬁcant differences are indicated as: ***P b 0.001 versus CTRL; +++P b 0.001 versus imatinib (10 μM); ΔΔΔP b 0.001 versus
imatinib (20 μM).
2001M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–2003autophagic cell death pathway, as denoted by accumulation autopha-
gic vacuoles and LC3A-II and LC3B-II, as well as the increase in
autophagic ﬂux, as indicated by p62 decrease. Paradoxically,
beclin-1, Atgs 3, 5 and 12 protein expressions were decreased, rather
than increased. It was recently suggested that beclin-1 is cleaved by
caspases during apoptosis in different cell lines [33,34]. This ﬁnding
is in agreement with our results, because pretreatment with
Z-VAD-FMK reversed the decline in the uncleaved beclin-1 and
prevented its cleavage due to nilotinib and resulted in both LC3A-II/
I and LC3B-II/I accrual. In addition to blocking nilotinib-induced apo-
ptosis, cyclosporin A efﬁciently blocked nilotinib-induced autophagic
cell death, as well as the potent induction observed by combining
nilotinib with Z-VAD-FMK. However, the autophagy inhibitor
3-methyladenine succeeded in preventing nilotinib-induced increase
LC3A-II/I and LC3B-II/I, but failed to inhibit this increase when
Z-VAD-FMK was included along with nilotinib.
One of the key events in themitochondrial death pathway is themi-
tochondrial outermembrane permeabilization, which unleashes death-
promoting factors that reside in the mitochondrial intermembrane
space, including cytochrome c, apoptosis-inducing factor (AIF), endo-
nuclease G (endo G) and HTRA2 [35,36]. AIF and endo G function in a
caspase-independent manner by relocating to the nucleus and mediat-
ing large-scale DNA fragmentation [37]. Our results suggest that AIF and
endo G have a minor role in DNA fragmentation induced by nilotinib,
because we could see only slight cleavage of PARP after pretreatmentwith Z-VAD-FMK. On the other hand, HTRA2 facilitates caspase activa-
tion by sequestering and/or degrading several members of XIAP, the in-
hibitor protein of apoptosis [37], which can block both the initiation
phase, by inhibiting caspase-9, and the execution phase, by blocking
caspase-3 and caspase-7, of the cascade [38]. Besides, HTRA2 also con-
tributes to caspase-independent apoptosis by cleaving a wide array of
cellular substrates, the most important are cytoskeletal proteins [39].
Accordingly, we investigated the effect of inhibition of HTRA2 on
nilotinib induced cytotoxicity by the use of the general serine protease
inhibitor AEBSF and the selective HTRA2 inhibitor UCF-101. Our results
support that HTRA2 effect in HSCs is not involved in autophagy, which
contradicts a recently published report [40].
We observed also for the ﬁrst time that application of nilotinib to
LX-2 cells resulted in the inhibition of the protein expression of
HDAC1, HDAC2 and more pronouncedly HDAC4 in a dose dependent
manner. Accordingly, nilotinib induced cytotoxicity for HSCs might be
related to the inhibition of HDACs. It has been reported that HDAC1,
but not HDAC2, is required for TGF-β1-induced epithelial–mesenchymal
transition, and its high expression level in majority of hepatocellular
carcinoma samples suggests that HDAC1 can be related with the inva-
siveness of hepatocellular carcinoma [41]. Most recently, it has been
reported that the expression level of HDAC4 profoundly increased
during HSCs' transdifferentiation and acted as a repressor for the
MMPs 9 and 13 [42]. Otherwise, Liu et al. have found that nilotinib
inhibited not only Smad2 signaling induced by TGF-β1, but also
Fig. 10. Nilotinib-induced apoptosis and autophagy are diverted towards necrosis by inhibition of histone acetyl transferases. Effects of pretreatment with AEBSF (100 μM), UCF-101
(2 μM) and C646 (1 μM) on nilotinib (20 μM)-induced cytotoxicity as evaluated under the phase contrast microscope (A) and by ﬂow cytometric analysis using AV-FITC (FL1-H)
and PI (FL2-H) staining (B–C), and the protein expression of PARP/cleaved PARP, LC3A-I/II and LC3B-I/II (A–C), beclin-1 (D−E) and pro-caspase 7/cleaved caspase 7 (D–I) as
assessed by Western blotting for the total lysates of LX-2 cells. Data are means ± SE of at least 4 independent experiments. Statistically signiﬁcant differences are indicated as:
*P b 0.05, **P b 0.01 and ***P b 0.001 versus CTRL; ∇∇∇P b 0.001 versus nilotinib (20 μM).
2002 M.E. Shaker et al. / Biochimica et Biophysica Acta 1833 (2013) 1992–2003phosphorylation of ERK and Akt stimulated by TGF-β1 in vivo during
CCl4 and BDL-induced liver ﬁbrosis. Akt is involved in TGF-β1-induced
down-regulation of MMP 13 expression [43]. Moreover, HDAC inhib-
itors have been shown to repress TGF-β1-induced ERK and PI3K/Akt
in ﬁbroblasts without altering the Smad pathway [44]. Taken these
ﬁndings together, nilotinib-induced inhibition of HDACs, and in par-
ticular HDAC4, might be the upstream for the up-regulation of MMPs
and subsequently, resolution of liver ﬁbrosis via degradation of ECM
proteins.
An unresolved question is how HDAC inhibitors induce cell death.
Recent studies suggest that acetylation of nonhistone proteins may
play an important role in the biological effects of this class of com-
pounds, and may explain lack of correlation between histone acetyla-
tion and induction of cell death by HDAC inhibitors in
some circumstances [45]. Pretreatment with the selective p300/CBP
histone acetyl transferase inhibitor C646 resulted in decreasing
nilotinib-induced apoptosis and diversion of apoptosis to necrosis
(as summarized in Supplementary Figs. 2 and 3). Besides, C646
resulted in a slight decrease in PARP cleavage and a complete sup-
pression of both LC3A-I and LC3B-I, as well as beclin-1. Besides,
C646 repressed constitutive basal caspases and there was no caspasecleavage. The last observation suggests that the upstream signaling
pathways of nilotinib-induced autophagy and apoptosis are
inhibited by C646, which resulted in caspases-independent postlytic
DNA damage rather than the caspases-dependent prelytic DNA dam-
age. When a cell is undergoing death and the mitochondria is not en-
suring its energy needs, caspase inhibition can switch apoptosis to
necrosis because of insufﬁcient ATP to support the active process of
apoptosis [46], and this was the case with C646 pretreatment to
block-nilotinib induced cell death. However, this was not the case
when we blocked caspase activation in nilotinib-treated LX-2 cells
because Z-VAD-FMK has no effect on mitochondria, and there was
no signiﬁcant increase in necrotic cells.
5. Conclusions
Our results indicate that the inhibition of HDACs by nilotinib is in-
volved in the apoptosis and autophagic cell death. Overall, this study
suggests that nilotinib may be valuable in the treatment of hepatic ﬁ-
brosis in humans.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbamcr.2013.02.033.
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